Kathrin I Foerster

8PUBLICATIONS
31CO-AUTHORS
PharmacogenomicsCheminformatics and quantitative structure-activity relationshipsMolecular targetsPharmaceutical delivery technologiesHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Feb 23, 2024
Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers.

Brit S Rohr, Evelyn Krohmer, Kathrin I Foerster

|Jul 28, 2023
CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults.

Amin Muhareb, Antje Blank, Andreas D Meid

|Jul 26, 2022
The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models.

Romain Sigaud, Lisa Rösch, Charlotte Gatzweiler

|Apr 23, 2022
Simultaneous Quantification and Pharmacokinetic Characterization of Doxapram and 2-Ketodoxapram in Porcine Plasma and Brain Tissue.

Manuel Kraft, Kathrin I Foerster, Felix Wiedmann

|Sep 28, 2021
Treatment with Edoxaban Attenuates Acute Stroke Severity in Mice by Reducing Blood-Brain Barrier Damage and Inflammation.

Michael Bieber, Kathrin I Foerster, Walter E Haefeli

|May 24, 2021
Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy.

Felix Wiedmann, Christoph Beyersdorf, Xiao Bo Zhou

Pageof 2

Frequent Collaborators

8 joint publications

Walter E Haefeli

4 joint publications

Gerd Mikus

4 joint publications

Jürgen Burhenne

3 joint publications

Antje Blank